Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on yesterday’s announcement that OncoZenge has carried out a directed share issue of SEK3.3m to Life Science Invest Fund (LSIF) and Selandia Alpha Invest.</li><li>While limited in size, we are encouraged to see existing specialist investors increasing their holdings only weeks after the completion of the rights issue, and the proceeds further strengthen the company’s cash position as the pivotal Phase III BEAM-Pain trial progresses.</li></ul>

Redeye comments on yesterday’s announcement that OncoZenge has carried out a directed share issue of SEK3.3m to Life Science Invest Fund (LSIF) and Selandia Alpha Invest.While limited in size, we are encouraged to see existing specialist investors increasing their holdings only weeks after the completion of the rights issue, and the proceeds further strengthen the company’s cash position as the pivotal Phase III BEAM-Pain trial progresses.

OncoZenge: SEK3.3m directed issue to specialist investors

Oncozenge

OncoZenge: SEK3.3m directed issue to specialist investors